Head-To-Head Comparison: Vectura Group (OTCMKTS:VEGPF) versus Vincerx Pharma (NASDAQ:VINC)

Risk & Volatility

Vincerx Pharma has a beta of 1.58, suggesting that its stock price is 58% more volatile than the S&P 500. Comparatively, Vectura Group has a beta of 0.37, suggesting that its stock price is 63% less volatile than the S&P 500.

Institutional & Insider Ownership

44.0% of Vincerx Pharma shares are owned by institutional investors. 15.6% of Vincerx Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Vincerx Pharma and Vectura Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vincerx Pharma	N/A	-248.33%	-132.73%
Vectura Group	N/A	N/A	N/A

Earnings and Valuation

This table compares Vincerx Pharma and Vectura Group”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vincerx Pharma	N/A	N/A	-$40.16 million	($5.31)	0.00
Vectura Group	$244.76 million	4.37	$157.16 million	$0.26	6.81

Vectura Group has higher revenue and earnings than Vincerx Pharma. Vincerx Pharma is trading at a lower price-to-earnings ratio than Vectura Group, indicating that it is currently the more affordable of the two stocks.

Summary

Vectura Group beats Vincerx Pharma on 6 of the 9 factors compared between the two stocks.

About Vincerx Pharma

Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors. The company's preclinical stage product candidates include VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is based in Palo Alto, California.

About Vectura Group

Vectura Group Plc engages in the provision of pharmaceutical development. Its activities include research, development, and commercialization of novel therapeutic products. The company operates through the following segments: Switzerland, United Kingdom, Germany, United States of America, and France. Vectura Group was founded by David Anthony Gough in 1997 and is headquartered in Chippenham, the United Kingdom.